Overview of antivenom allocation and use for snakebites in the Brazilian Amazon

  Overview of antivenom allocation and use for snakebites in the Brazilian Amazon Abstract Venomous snakebites affect many people in the Amazon annually. We analyzed the dynamics of the allocation and use of antivenoms in the Brazilian Amazon between 2010 and 2024. Of the 1,304,681 vials allocated to the region, 945,578 (72.5%) were administered, the majority of which were Bothrops antivenom (735,516 vials). The high level of actual antivenom use underscores the significance of this region regarding demand for antivenom treatment in Brazil. Martins, J. G., Pardal, P. P. D. O., & Procópio, R. E. D. L. (2027). Overview of antivenom allocation and use for snakebites in the Brazilian Amazon. Toxicon , 285 , 109347. https://doi.org/10.1016/j.toxicon.2026.109347

VIROCIDAL ACTIVITY OF EGYPTIAN SCORPION VENOMS AGAINST HEPATITIS C VIRUS

 


VIROCIDAL ACTIVITY OF EGYPTIAN SCORPION VENOMS AGAINST HEPATITIS C VIRUS

Abstract

Hepatitis C virus (HCV) is a major global health problem, causing chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Development of well-tolerated regimens with high cure rates and fewer side effects is still much needed. Recently, natural antimicrobial peptides (AMPs) are attracting more attention as biological compounds and can be a good template to develop therapeutic agents, including antiviral agents against a variety of viruses. Various AMPs have been characterized from the venom of different venomous animals including scorpions.


Xojimurodov Davronjon Ikramaliyevich, & Mirzayev Furqat Farhod o'g'li. (2024). VIROCIDAL ACTIVITY OF EGYPTIAN SCORPION VENOMS AGAINST HEPATITIS C VIRUS. Multidisciplinary Journal of Science and Technology, 4(2), 169–173. Retrieved from https://mjstjournal.com/index.php/mjst/article/view/829